Items for which less than half of the participants knew included (from low to high): item 11 (the interval between two injections at the same site; 23%), item 21 (hypoglycemia management; 26%), item 1 (types of aspartic insulin; 36%), item 17 (needle disposal method; 36%), item 19 (mixing method for insulin; 39%), and item 18 (injection site administration after withdrawal of needle; 40%). This evidence concerns the gene INS and Hypoglycemia.